Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 20 2023 - 11:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of March, 2023
Commission File Number 001-39670
PURETECH HEALTH PLC
(Translation of registrants name into English)
6 Tide
Street, Suite 400
Boston, Massachusetts 02210
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 20, 2023, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the Company) issued a press release titled PureTech Founded
Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia.
The press release issued by the Company is furnished herewith as Exhibit 99.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PURETECH HEALTH PLC |
|
|
|
Date: March 20, 2023 |
|
By: |
|
/s/ Daphne Zohar |
|
|
|
|
Name: |
|
Daphne Zohar |
|
|
|
|
Title: |
|
Chief Executive Officer |
Puretech Health (PK) (USOTC:PTCHF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Puretech Health (PK) (USOTC:PTCHF)
Historical Stock Chart
From Oct 2023 to Oct 2024